Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Abstract

BACKGROUND Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non–small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute–Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621.)

Well‐controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report

“…Secondly, pseudoprogression cannot be ruled out after primary tumor progression . In a recent report, the larger tumor mass detected after the administration of nivolumab only contained immune cells and no tumor cells . Thirdly, the later reduction of the primary tumor was possibly a result of the addition of chemotherapy, which modulated the inflammation millieu …”

Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients

“…Clinical evidence has suggested that patients can experience long-term PFS if the immune checkpoint inhibitor is discontinued due to side effects in response [1,[11][12][13]. Interestingly, a recent neoadjuvant study in the field of NSCLC has shown that 45% of patients show major tumor responses even after a short (4 weeks) PD-1 therapy [16]. Since our institute has limited maximal continuous PD-(L)1 inhibitor therapy to 6 months, our cohort provides a unique opportunity to study the effects of a shorter immune checkpoint inhibitor therapy length than until progression in the absence of severe immune-mediated side effects.…”

Total necrosis after sequential treatment with pazopanib followed by nivolumab in a patient with renal cell carcinoma involving the inferior vena cava

“…Previously, only one RCC patient with a complete pathological response after nivolumab was reported and a few other cases were reported for melanoma and lung cancer . However, this is the first report in which a surgical specimen showed total necrosis after treatment with nivolumab, even though the tumor mass was still present in both the kidney and IVC extending to just above the diaphragm.…”